Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Keller, J.
  • Catala-Lehnen, P.
  • Huebner, A. K.
  • Jeschke, A.
  • Heckt, T.
  • Lueth, A.
  • Krause, M.
  • Koehne, T.
  • Albers, J.
  • Schulze, J.
  • Schilling, S.
  • Haberland, M.
  • Denninger, H.
  • Neven, M.
  • Hermans-Borgmeyer, I.
  • Streichert, T.
  • Breer, S.
  • Barvencik, F.
  • Levkau, B.
  • Rathkolb, B.
  • Wolf, E.
  • Calzada-Wack, J.
  • Neff, F.
  • Gailus-Durner, V.
  • Fuchs, H.
  • de Angelis, M. H.
  • Klutmann, S.
  • Tsourdi, E.
  • Hofbauer, L. C.
  • Kleuser, B.
  • Chun, Jerold
  • Schinke, T.
  • Amling, M.

publication date

  • October 2014

journal

  • Nature Communications  Journal

abstract

  • The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P3. Finally, pharmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type, but not in S1P3-deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.

subject areas

  • Alleles
  • Animals
  • Bone and Bones
  • Calcitonin
  • Collagenases
  • Crosses, Genetic
  • Female
  • Lysophospholipids
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Osteoblasts
  • Osteoclasts
  • Osteogenesis
  • Osteoporosis
  • Phenotype
  • Porosity
  • Receptors, Calcitonin
  • Signal Transduction
  • Sphingosine
scroll to property group menus

Identity

PubMed Central ID

  • PMC4205484

International Standard Serial Number (ISSN)

  • 2041-1723

Digital Object Identifier (DOI)

  • 10.1038/ncomms6215

PubMed ID

  • 25333900
scroll to property group menus

Additional Document Info

start page

  • 5215

volume

  • 5

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support